Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Theravance Biopharma (TBPH) over the last 12 years, with Q3 2025 value amounting to $174.8 million.

  • Theravance Biopharma's Cash & Equivalents rose 64759.6% to $174.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $174.8 million, marking a year-over-year increase of 64759.6%. This contributed to the annual value of $37.8 million for FY2024, which is 442.03% down from last year.
  • Latest data reveals that Theravance Biopharma reported Cash & Equivalents of $174.8 million as of Q3 2025, which was up 64759.6% from $281.9 million recorded in Q2 2025.
  • Theravance Biopharma's Cash & Equivalents' 5-year high stood at $418.5 million during Q3 2022, with a 5-year trough of $23.4 million in Q3 2024.
  • Over the past 5 years, Theravance Biopharma's median Cash & Equivalents value was $105.6 million (recorded in 2023), while the average stood at $134.8 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 8673.75% in 2023, then surged by 64759.6% in 2025.
  • Quarter analysis of 5 years shows Theravance Biopharma's Cash & Equivalents stood at $90.0 million in 2021, then skyrocketed by 231.45% to $298.2 million in 2022, then tumbled by 86.74% to $39.5 million in 2023, then fell by 4.42% to $37.8 million in 2024, then soared by 362.4% to $174.8 million in 2025.
  • Its Cash & Equivalents was $174.8 million in Q3 2025, compared to $281.9 million in Q2 2025 and $110.6 million in Q1 2025.